Advertise with NationWire
728 × 90 Leaderboard
Advertise Here
Politics

White House Drops Heidi Overton’s FDA Nomination Ahead of Senate Vote

Advertise with NationWire
300 × 250 Medium Rectangle
Advertise Here

The White House withdrew Dr Heidi Overton’s nomination to lead the Food and Drug Administration on Tuesday, 17 November, hours before a Senate committee was due to vote on whether to advance her to the full Senate.

The decision, confirmed by a White House official and first reported by Axios, ends a nomination that had been in serious doubt for days. Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by President Donald Trump in August to succeed Dr Marty Makary, who resigned as FDA commissioner in May.

The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on the nomination at 10 a.m. on Wednesday, 18 November. That vote will no longer take place.

The votes were not there

Overton faced a narrow path through the committee. Republicans hold 12 of its 23 seats, with Democrats holding 11, meaning she needed the support of every Republican on the panel to advance if Democrats opposed her, as expected.

Several Republican senators declined on Tuesday to say how they planned to vote, including Lisa Murkowski of Alaska and Josh Hawley of Missouri. Committee chairman Bill Cassidy, a Louisiana physician, said earlier in the day that he remained undecided.

Cassidy had previously called Overton’s support for breaking up combination vaccines — including the measles, mumps and rubella shot — “almost disqualifying”. At her confirmation hearing in September, senators from both parties pressed her on whether she would be willing to break from the president, particularly on his unsupported claims about the dangers of childhood vaccines.

The Associated Press reported that the White House acted after growing indications that Overton did not have the votes needed to win confirmation.

Abortion pill and vaping drew the sharpest fire

Two issues dominated the opposition to Overton: the abortion pill mifepristone and flavoured vaping products.

Overton, a prominent opponent of abortion who has praised the Supreme Court’s decision to overturn Roe v. Wade, was criticised during her hearing for not taking a clear position on mifepristone. Senator Murkowski pressed her on political pressure surrounding access to the drug, and anti-abortion groups urged senators to oppose her unless the administration promised to speed up a thorough review of the pill. The FDA is set to finish its safety review of mifepristone in March 2027.

On vaping, Overton defended the FDA’s May decision to authorise the first fruit-flavoured e-cigarettes for adult smokers, telling senators there was evidence the flavours could help some adults quit smoking. The stance drew fierce criticism from supporters of Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again movement, who view her as aligned with the food and drug industries.

Former Kennedy adviser Calley Means said this month that Overton wrote a policy relaxing standards for fruit-flavoured vapes, and an anonymous advocacy group calling itself Health in Office launched a campaign branding her “Heidi Vaperton”, with posters and yard signs placed around Washington over the weekend.

A long vacancy at the top of the FDA

The FDA, which regulates products accounting for about a fifth of US consumer spending, has now been without a Senate-confirmed commissioner for six months. It is currently led on an acting basis by Kyle Diamantas, an attorney and friend of Donald Trump Jr.

The agency has been without a permanent leader since May, when Dr Marty Makary resigned — a vacancy that has already shaped other FDA decisions, including the shelving of a Makary-era fast-track drug review voucher. The agency has continued to operate in the meantime, and earlier this month it fast-tracked a sleep drug for children with insomnia.

It was not immediately clear when the White House might put forward another nominee. Reuters reported that the administration is weighing Senator Roger Marshall of Kansas, a former obstetrician, as a possible replacement, while CBS News reported that Marshall is making a play for the post.

A narrowing window for confirmations

The withdrawal comes as Republicans race to confirm Trump’s nominees before Democrats take control of Congress in January, following the midterm elections. Dozens of nominations remain pending, and the loss of a high-profile pick will add pressure to a calendar that is already tight.

For the White House, the episode exposes a fault line inside the administration’s own coalition: the Make America Healthy Again movement, led by Kennedy, and more traditional conservative circles pulled in opposite directions over Overton, and the White House ultimately chose to pull the nomination rather than risk a public defeat in committee.

The committee had also been due to vote on Wednesday on other nominees, including Jim O’Neill, the pick to lead the National Science Foundation. Those votes are expected to proceed.

Advertise with NationWire
320 × 50 Mobile Banner
Advertise Here

Leave a Reply

Your email address will not be published. Required fields are marked *